Similar to other published data,2, 13 this combined HNSCC cohort shows TMB did not correlate with PD‐L1 or TcellinfGEP but rather indicates mutational load acted as an additional explanatory axis for objective response to pembrolizumab in this pooled analysis. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.